Effects of intraseptally injected noradrenergic drugs on hippocampal sodium-dependent-high-affinity-choline-uptake in 'resting' and 'trained' mice.
It has been shown in numerous studies that memory testing can alter presynaptic cholinergic activity within the hippocampus. In the present experiments, the role of the noradrenergic input to the septal cholinergic neurons in the immediate increase in cholinergic activity induced by the first training session of a spatial reference memory task in an 8-arm radial maze was investigated. The effects of bilateral intraseptal injections of noradrenergic drugs on hippocampal sodium-dependent-high-affinity-choline-uptake (SDHACU) were studied in 'resting' animals (basal level) or in 'trained' animals injected 20 min before training and sacrificed immediately after the test. The results showed that: (1) the injection of maprotiline, a noradrenaline reuptake inhibitor (0.06 ng/site), induced an increase in hippocampal SDHACU in 'resting' animals, whereas the alpha 2-adrenoceptor agonist UK 14304 (1.5 ng) significantly reduced the basal level of SDHACU; (2) none of the alpha-adrenoceptor antagonists used (phenoxybenzamine, 10 and 100 ng; BE 2254, 100 and 500 ng; yohimbine, 0.5 and 50 ng) significantly affected the basal level of hippocampal SDHACU, and only the alpha 1-adrenoceptor antagonist BE 2254 (500 ng) significantly reduced the testing-induced activation of SDHACU. Taken together, these findings suggest that noradrenaline may exert a bimodal regulatory influence on the activity of septo-hippocampal cholinergic neurons. The behavior-induced activation of hippocampal SDHACU could be partly mediated by the stimulation of alpha 1-adrenoceptors, whereas postsynaptic alpha 2-adrenoceptors may be important for the maintenance of a tonic inhibition of the steady-state cholinergic activity in the hippocampus.(ABSTRACT TRUNCATED AT 250 WORDS)
Marighetto
A
A
Laboratoire de Neurosciences Comportementales et Cognitives, CNRS URA 339, Université de Bordeaux I, Talence, France.
Jaffard
R
R
Micheau
J
J
D018663:Adrenergic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002794:Choline / Q000378:metabolism*; D004193:Discrimination Learning / Q000502:physiology*; D004192:Discrimination, Psychological / Q000187:drug effects; D006624:Hippocampus / Q000378:metabolism*; D008297:Male; D008376:Maprotiline / Q000494:pharmacology; D008570:Memory, Short-Term / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009638:Norepinephrine / Q000502:physiology*; D010627:Phenethylamines / Q000494:pharmacology; D012964:Sodium / Q000502:physiology*; D013569:Synapses / Q000502:physiology; D044024:Tetralones
D018663:Adrenergic Agents; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D010627:Phenethylamines; D044024:Tetralones; D008376:Maprotiline; C010652:BE 2254; D012964:Sodium; D002794:Choline; D009638:Norepinephrine